Cardiol Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDL research report →
Range $8 – $8
Price Chart
About the company
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial.
- CEO
- David G. Elsley
- IPO
- 2019
- Employees
- 18
- HQ
- Oakville, ON, CA
Get TickerSpark's AI analysis on CRDL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $110.14M
- P/E
- -3.74
- Fwd P/E
- 2.66
- PEG
- -0.15
- P/S
- 0.00
- P/B
- 5.34
- EV/EBITDA
- -3.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -159.80%
- ROIC
- -128.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-34,316,296
- Net Income
- $-33,818,874+7.8%
- EPS
- $-0.39+23.5%
- OCF Growth
- +4.8%
- FCF Growth
- +4.8%
- 52W High
- $2.34
- 52W Low
- $0.84
- 50D MA
- $1.30
- 200D MA
- $1.30
- Beta
- 0.52
- RSI (14)
- 26
- Avg Volume
- 1.20M
No earnings-call transcripts are available for CRDL yet.
- Free Float
- 76.2%
- Shares Outstanding
- 120.66M
- Float Shares
- 91.98M
of shares held by institutions
55 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mmcap International Inc. Spc | 15.60M | 0 |
| Tejara Capital Ltd | 7.42M | ▲ 2.31M |
| Ikarian Capital, LLC | 3.33M | 0 |
| Ameriprise Financial Inc | 2.25M | ▲ 2.25M |
| Woodline Partners LP | 2.23M | ▲ 2.23M |
| J. Goldman & Co LP | 1.94M | ▲ 1.94M |
| Point72 Asset Management, L.P. | 1.74M | ▲ 1.72M |
| Two Sigma Investments, LP | 1.09M | ▲ 344.71K |
| Morgan Stanley | 1.01M | ▲ 655.66K |
| Boothbay Fund Management, LLC | 975.72K | 0 |
| Citadel Advisors LLC | 486.25K | ▼ 310.28K |
| Goldman Sachs Group Inc | 376.80K | ▲ 42.90K |
Held by 1 ETFs
Biggest fund positions in CRDL by dollar value.
Our CRDL coverage
Recent articles, reports, and earnings notes.
No research on CRDL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRDL report →Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
prnewswire.com · Nov 3
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
prnewswire.com · Sep 23
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
prnewswire.com · Sep 16
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
zacks.com · Sep 14
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
prnewswire.com · Sep 10
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 9
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
zacks.com · Aug 25
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
zacks.com · Aug 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.